Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 20 for t cell lymphoma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Testing Whether High Dose Chemotherapy And Infusion Of The Patients' Own Stem Cells Improves Survival In Patients With Peripheral T-cell Lymphoma Who Achieved A Complete Response At The End Of The Initial Chemotherapy

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

    Scottsdale/Phoenix, AZ

  3. Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

    Jacksonville, FL, Rochester, MN

  4. A Phase 1/​2 Study of STP938 for Adult Subjects With Relapsed/​Refractory B-Cell and T-Cell Lymphomas

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  6. CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies

    Rochester, MN

  7. Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

  8. Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Confirmatory Study of Topical HyBryte™ Vs. Placebo for the Treatment of CTCL (FLASH2)

    Scottsdale/Phoenix, AZ

  10. A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL

.

Mayo Clinic Footer